Pembrolizumab plus platinum-based chemotherapy for squamous non-small cell lung cancer: the new kid on the block
Affiliation
Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UKIssue Date
2021
Metadata
Show full item recordCitation
Hockenhull K, Ortega-Franco A, Califano R. Pembrolizumab plus platinum-based chemotherapy for squamous non-small cell lung cancer: the new kid on the block [Internet]. Vol. 10, Translational Lung Cancer Research. AME Publishing Company; 2021. p. 3850–4.Journal
Translational Lung Cancer ResearchDOI
10.21037/tlcr-20-715PubMed ID
34733633Additional Links
https://dx.doi.org/10.21037/tlcr-20-715Type
OtherLanguage
enae974a485f413a2113503eed53cd6c53
10.21037/tlcr-20-715
Scopus Count
Collections
Related articles
- Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
- Authors: Garassino MC, Gadgeel S, Esteban E, Felip E, Speranza G, Domine M, Hochmair MJ, Powell S, Cheng SY, Bischoff HG, Peled N, Reck M, Hui R, Garon EB, Boyer M, Wei Z, Burke T, Pietanza MC, Rodríguez-Abreu D
- Issue date: 2020 Mar
- Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
- Authors: Borghaei H, Langer CJ, Paz-Ares L, Rodríguez-Abreu D, Halmos B, Garassino MC, Houghton B, Kurata T, Cheng Y, Lin J, Pietanza MC, Piperdi B, Gadgeel SM
- Issue date: 2020 Nov 15
- Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
- Authors: Chouaid C, Bensimon L, Clay E, Millier A, Levy-Bachelot L, Huang M, Levy P
- Issue date: 2019 Jan
- Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study.
- Authors: Gadgeel SM, Stevenson JP, Langer CJ, Gandhi L, Borghaei H, Patnaik A, Villaruz LC, Gubens M, Hauke R, Yang JC, Sequist LV, Bachman R, Saraf S, Raftopoulos H, Papadimitrakopoulou V
- Issue date: 2018 Nov